KPTI News and Press, Karyopharm Therapeutics Inc. From 11/03/21

Karyopharm Therapeutics Inc. (KPTI) Q3 2021 Earnings Conference Call November 03, 2021 08:30 AM ET Company Participants Jason Finkelstein - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Sh...

Karyopharm Therapeutics (KPTI +26.8%) has added more than a quarter of value recording the biggest intraday gain since March 2020 after the company’s Q3 2021 revenue toped analyst estimates. Net product revenue for the quarter surged ~25% YoY to reach $26.7M as U.S. net product sales f...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +110%, iRhythm Technologies IRTC +44%, Karyopharm Therapeutics KPTI +31%, Glaukos GKOS +25%, Rafael RFL +15%. Losers: Cardiol Therapeutics CRDL -25%, Bone Biologics (OTCPK:BBLG) -15%, ...

Karyopharm Therapeutics (NASDAQ:KPTI): Q3 GAAP EPS of -$0.69 misses by $0.01. Revenue of $37.69M (+76.7% Y/Y) beats by $11.4M. Shares +0.52% PM. Press Release 2021 Outlook: Non-GAAP R&D and SG&A expenses, excluding stock-based compensation expense, are expected to be in the range...

Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights -- Third Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year -- -- Milestone-Driven Q4 with ...

Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.68 and the consensus Revenue Estimate is $26.29M (+23.3% Y/Y). In September, Seeking Alpha contributor Biologics believes t...

AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...

Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , Oct. 27, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI...

Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome PR Newswire NEWTON, Mass. , Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage p...

Karyopharm Therapeutics has been on my watch list for several years. Sadly, my buy conditions never manifested for me to establish a position. Now I am looking for an entry. I believe Karyopharm’s current valuation along with its upside potential will eventually bring in some b...